AI note-taking tools spread through hospitals and medical schools — rules haven't caught up
A U.K. regulator is weighing whether AI "scribes" that draft clinical notes count as medical devices, while U.S. medical schools separately debate letting students use the same tools.
What happened: STAT News reports that a U.K. regulator has weighed in on a question that's been hanging over the fast-growing AI scribe industry: should these tools, which listen to patient visits and draft clinical notes, be regulated as medical devices? The decision has proven controversial, according to STAT's reporting, though the underlying dispute is over how much safety scrutiny these products should face. Separately, STAT's Morning Rounds newsletter reports that U.S. medical schools are quietly working out, program by program, whether students in training should be allowed to use AI scribes at all — with no clear national guidance yet from the organizations that oversee medical education.
Why it matters: AI scribes are already widely used by practicing doctors, who say they cut the hours spent typing notes after hours and reduce burnout. But two open questions now matter a lot: whether regulators treat these tools with the same scrutiny as other medical software, and whether letting medical students rely on them too early undermines the skill of writing notes — which some educators say is really the skill of thinking clearly about a patient's case.
How it works, plainly: An AI scribe listens to (or transcribes) a clinical conversation and generates a draft note in the format doctors typically use, which the clinician then reviews and edits before it goes in the chart. Whether that counts as a "medical device" affects how it's regulated: device status typically triggers safety and performance review plus ongoing monitoring, while non-device software generally faces lighter oversight. In medical schools, the debate is different — it's about whether writing your own notes, described by one Yale associate dean as a way of "wrestling with what's happening" in a case, is a skill worth protecting even if it's slower.
The rollout: There's no unified path yet. U.K. regulatory action on device classification could influence how other countries treat AI scribes, but the specifics of that decision and its consequences remain contested, per STAT. In the U.S., medical schools are largely improvising their own policies on student scribe use in the absence of guidance from national medical education bodies, meaning practices likely vary widely from campus to campus until — or unless — clearer standards emerge.